Market Closed -
Nasdaq
01:30:00 10/05/2024 am IST
|
5-day change
|
1st Jan Change
|
1.26
USD
|
-1.56%
|
|
0.00%
|
-26.32%
|
Fiscal Period: April |
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
54.12
|
53.62
|
168.3
|
86.92
|
45.37
|
-
|
-
|
Enterprise Value (EV)
1 |
54.12
|
53.62
|
168.3
|
86.92
|
45.37
|
45.37
|
45.37
|
P/E ratio
|
-
|
-
|
-
|
-3.19
x
|
-3.59
x
|
-4.86
x
|
-10.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.95
x
|
3.81
x
|
8.67
x
|
4.21
x
|
1.85
x
|
1.52
x
|
1.25
x
|
EV / Revenue
|
4.95
x
|
3.81
x
|
8.67
x
|
4.21
x
|
1.85
x
|
1.52
x
|
1.25
x
|
EV / EBITDA
|
-1,38,80,319
x
|
1,02,49,58,603
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
13,588
|
13,848
|
23,539
|
24,965
|
26,315
|
-
|
-
|
Reference price
2 |
2.974
|
2.775
|
5.560
|
2.570
|
1.260
|
1.260
|
1.260
|
Announcement Date
|
28/08/19
|
28/08/20
|
29/07/22
|
10/07/23
|
-
|
-
|
-
|
Fiscal Period: April |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
10.93
|
14.06
|
-
|
19.4
|
20.66
|
24.59
|
29.82
|
36.38
|
EBITDA
|
-3.899
|
0.0523
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-4.553
|
-
|
-16.75
|
-28.55
|
-13.84
|
-9.147
|
-4.273
|
Operating Margin
|
-
|
-32.39%
|
-
|
-86.33%
|
-138.16%
|
-56.3%
|
-30.68%
|
-11.74%
|
Earnings before Tax (EBT)
1 |
-
|
-5.293
|
-
|
-15.85
|
-27.75
|
-13.13
|
-9.147
|
-4.273
|
Net income
1 |
-
|
-4.947
|
-7.34
|
-16.7
|
-26.56
|
-12.13
|
-9.147
|
-4.273
|
Net margin
|
-
|
-35.19%
|
-
|
-86.08%
|
-128.53%
|
-49.33%
|
-30.68%
|
-11.74%
|
EPS
2 |
-
|
-
|
-
|
-
|
-0.8052
|
-0.3510
|
-0.2590
|
-0.1180
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/08/19
|
28/08/20
|
28/07/21
|
29/07/22
|
10/07/23
|
-
|
-
|
-
|
Fiscal Period: April |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
4.7
|
4.815
|
5.2
|
4.7
|
5.2
|
5.171
|
5.621
|
5.688
|
6.15
|
6.221
|
6.53
|
6.8
|
7.4
|
7.5
|
8.1
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.688
|
-4.307
|
-4.287
|
-10.07
|
-7.824
|
-4.58
|
-6.076
|
-4.177
|
-3.023
|
-3.34
|
-3.303
|
-
|
-
|
-
|
-
|
Operating Margin
|
-99.74%
|
-89.45%
|
-82.44%
|
-214.3%
|
-150.46%
|
-88.57%
|
-108.09%
|
-73.44%
|
-49.15%
|
-53.69%
|
-50.58%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-4.819
|
-3.618
|
-4.369
|
-9.784
|
-7.477
|
-4.595
|
-5.897
|
-3.827
|
-2.59
|
-3.457
|
-3.253
|
-
|
-
|
-
|
-
|
Net income
1 |
-5
|
-3.826
|
-4.644
|
-9.4
|
-7.351
|
-4.699
|
-5.13
|
-3.565
|
-2.622
|
-2.94
|
-3.003
|
-
|
-
|
-
|
-
|
Net margin
|
-106.38%
|
-79.46%
|
-89.31%
|
-200%
|
-141.37%
|
-90.87%
|
-91.26%
|
-62.68%
|
-42.63%
|
-47.26%
|
-45.99%
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-
|
-
|
-
|
-0.2199
|
-0.1382
|
-0.1505
|
-0.1035
|
-0.0737
|
-0.0814
|
-0.0850
|
-0.0740
|
-0.0440
|
-0.0590
|
-0.0740
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/12/21
|
16/03/22
|
29/07/22
|
14/09/22
|
15/12/22
|
16/03/23
|
10/07/23
|
14/09/23
|
14/12/23
|
14/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: April |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-0.6000
|
-0.1400
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/08/19
|
28/08/20
|
28/07/21
|
29/07/22
|
10/07/23
|
-
|
-
|
-
|
Last Close Price
1.28
USD Average target price
7
USD Spread / Average Target +446.88% Consensus |
1st Jan change
|
Capi.
|
---|
| -26.32% | 33.16M | | -2.38% | 88.47B | | +2.76% | 40.71B | | -13.92% | 32.43B | | +50.51% | 24.28B | | -15.25% | 15.52B | | -39.93% | 12.17B | | -9.08% | 12B | | -14.80% | 12.01B | | +6.22% | 8.87B |
Biopharmaceuticals
|